SomnoMed Limited (ASX:SOM)
Australia · Delayed Price · Currency is AUD 0.3350
+0.0050 (1.52%)
Aug 28, 2026, 4:10 PM AEST
SomnoMed Stock Forecast
Stock Price Forecast
According to 3 analysts polled by S&P Global, SomnoMed stock has a consensus rating of "Strong Buy" and an average price target of $0.95. The average 1-year stock price forecast is 183.58% higher than the current stock price, while the lowest is $0.75 (+123.88%) and the highest is $1.09 (+225.37%).
Price Target: $0.95 (+183.58%)
Analyst Consensus: Strong Buy
Price Target
Chart* Price targets were last updated on Jul 29, 2026.
Analyst Ratings
The average analyst rating for SomnoMed stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '26 | Mar '26 | Apr '26 | Jun '26 | Jul '26 | Aug '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 3 | 3 | 3 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Morgans | Morgans | Buy Maintains $0.75 | Buy | Maintains | $0.75 | +123.88% | Jul 29, 2026 |
| Canaccord Genuity | Canaccord Genuity | Buy Maintains $1.00 | Buy | Maintains | $1.00 | +198.51% | Apr 16, 2026 |
Financial Forecast
Revenue This Year
129.53M
from 114.53M
Increased by 13.09%
Revenue Next Year
141.02M
from 129.53M
Increased by 8.87%
EPS This Year
0.03
EPS Next Year
0.03
from 0.03
Increased by 33.51%
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is AUD.